<DOC>
	<DOCNO>NCT02888236</DOCNO>
	<brief_summary>A study LEO 32731 treatment psoriasis vulgaris</brief_summary>
	<brief_title>LEO 32731 Treatment Moderate Severe Psoriasis Vulgaris</brief_title>
	<detailed_description>This investigation efficacy LEO 32731 30 mg compare placebo 16 week oral treatment psoriasis vulgaris</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed date informed consent Aged 18 year 65 . Males females nonchildbearing potential . Clinical diagnosis psoriasis vulgaris without psoriatic arthritis Have moderate severe psoriasis vulgaris Candidates systemic antipsoriatic treatment and/or phototherapy Subjects therapy resistant psoriasis Previously expose apremilast Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris Systemic treatment therapy ( biologics ) possible effect psoriasis vulgaris</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>